FRIDAY, July 29, 2022 (HealthDay News) -- For patients with prostate cancer, use of androgen-deprivation therapy (ADT) is associated with an increased risk for cardiovascular disease (CVD) death, according to a study published online July 26 in The Aging Male. Justinas Jonusas, from the National Cancer Institute in Vilnius, Lithuania, and colleagues examined the risk